Sponsored Content

Glac Biotech Launches Clinically Tested Postbiotic Ingredients for Oral and Intestinal Health

Postbiotics, which consist of inanimate microorganisms and their metabolites, have become a validated class of ingredients supported by a large amount of science evidence showing similar outcomes to probiotics without the challenges of thermo-limitation. Glac Biotech, a contract manufacturer at the forefront of postbiotics in Taiwan, has been able to launch clinically proven ingredients：Totipro® PE0301(Oral Health) and Totipro® PE0401(Intestine Health).

Research into postbiotics has exploded recently, with increasing consumer’s awareness and popularity  as its advantage of nutrient-rich, breakdown of thermo-limitation, variety of application in foods and beverages. Glac Biotech offers clinically validated postbiotic ingredients, which is an emerging opportunity for nutraceutical supplements, foods and beverages, and the healthy products industry for it can be a new option to their product formulations and potential applications.

Glac Totipro® Postbiotics Ingredients including Totipro® PE0301 and Totipro® PE0401. Totipro® PE0301 enhances oral health and salivary immunity, and Totipro® PE0401 improves digestive health and reduces cholesterol, blood sugar, and uric acid levels. 

Both of the postbiotic ingredients are essence of fermented multi-strain probiotics that show beneficial health effects similar to live probiotics but with the advantage of being thermo-stable. 

This breakthrough technology creates more possibilities for nutraceutical applications. Through Glac exclusive fermentation process, our postbiotic products retain most of the nutrients and have been clinically proven effective, manufacturing in an internationally standardized, computer-automated factory, ensuring quality and safety.

Read More